Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Canopy Growth (CGC)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Eli Lilly & Co (LLY – Research Report) and Canopy Growth (CGC – Research Report).
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Eli Lilly & Co (LLY)
Bernstein analyst Courtney Breen assigned a Buy rating to Eli Lilly & Co on February 6 and set a price target of $1300.00. The company’s shares closed last Friday at $1058.18.
According to TipRanks.com, Breen is a 5-star analyst with an average return of
Currently, the analyst consensus on Eli Lilly & Co is a Strong Buy with an average price target of $1258.71, which is a 19.2% upside from current levels. In a report issued on January 27, Citi also maintained a Buy rating on the stock with a $1500.00 price target.
See today’s best-performing stocks on TipRanks >>
Canopy Growth (CGC)
In a report issued on February 6, Nadine Sarwat from Bernstein maintained a Hold rating on Canopy Growth, with a price target of $1.80. The company’s shares closed last Friday at $1.10, close to its 52-week low of $0.98.
According to TipRanks.com, Sarwat is a 1-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Canopy Growth with a $2.99 average price target, implying a 174.3% upside from current levels. In a report issued on February 6, Alliance Global Partners also maintained a Hold rating on the stock with a C$1.80 price target.
